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ABSTRACT 
The lymphatic system is a network of organs and vessels that serve different purposes including 
the filtering of blood and the initiation of an immune response to an infection.  Lymphedema is 
the swelling of the arm(s) and/or leg(s) from removal, damage, or blockage of the lymphatic 
system.  Lymphedema can occur as a secondary condition caused by another disease or 
condition, but lymphedema can also be inherited.  Cystic hygroma is a collection of lymphatic 
fluid at the back of the neck that may be observed during a prenatal ultrasound exam and then 
disappear on its own, although sometimes it is still present at birth.  Some evidence suggests that 
one cause of cystic hygroma is inherited lymphedema.   Inherited lymphedema and cystic 
hygromas are findings that may require treatment and follow-up. If an association exists between 
cystic hygromas and inherited lymphedema, then establishing this connection can help predict 
prognosis and provide appropriate care at both the individual level and the population level for 
public health significance.   
An introduction letter and cystic hygroma questionnaire were sent out to the participants 
of the University of Pittsburgh’s Lymphedema Family Study who have voluntarily provided their 
own biological samples previously (1,628 people).  The questionnaire was completely voluntary 
and was either mailed or faxed back when completed.  It inquired about lymphedema, cystic 
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hygromas, and prognosis.  It also inquired about other biological family members including 
babies that did not survive to birth.  Follow-up phone calls were made to some families for 
clarification.   
 Results show that 316 (19.4%) research participants have completed and returned the 
questionnaire, 2.44% of those that returned the questionnaire and have lymphedema also had 
cystic hygromas, and 0.57% of those without lymphedema that returned the questionnaire had 
cystic hygromas.  This difference in cystic hygroma prevalence is not statistically significant (p = 
0.3094).  However, there is some enough evidence to support the claim that there is a higher 
prevalence of cystic hygromas in those with lymphedema compared to the general population 
(18.3-fold difference).  It is possible that the number of individuals diagnosed with cystic 
hygromas is underreported because prenatal ultrasounds were not available for many 
participants.   
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1.0  INTRODUCTION 
The lymphatic system is a network of organs and vessels that serve different purposes including 
aiding the immune system.  Lymphedema is the swelling that occurs typically in the arms and 
legs due to blockage, damage, or malformation of the lymphatic vessels.  Primary lymphedema 
is an inherited condition, but may have an unknown cause.  Secondary lymphedema is caused by 
an external process such as surgery, infection, radiation, or cancer.  Cystic hygromas are fluid-
filled growths that typically occur in the neck or head area due to partial malformation of the 
lymphatic system.  Cystic hygromas are found prenatally via ultrasound, at birth, or within the 
first couple years of life.  Fifty to sixty percent of cystic hygroma cases also have a chromosomal 
condition that can be detected by karyotype.  
The Lymphedema Family Study is a University of Pittsburgh study designed to serve and 
do research on families with lymphedema and has been active since 1995.  There were 2,229 
biological sample kits and surveys sent out for the Lymphedema Family Study.  The survey has 
identified 7 individuals that have both lymphedema and cystic hygromas (plus one individual 
with lymphedema that may have had a cystic hygroma) through the free-response section of the 
survey.  The purpose of this current study is to explicitly investigate a possible association 
between primary lymphedema and cystic hygromas with the questionnaire shown in Appendix B 
and to help establish prognosis for those with both primary lymphedema and cystic hygromas.  If 
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an association exists between primary lymphedema and cystic hygromas, then this knowledge 
can help predict prognosis and provide appropriate care.                       
1.1 AIMS 
 
Aim 1: To ascertain the proportion of people with cystic hygromas of those with and without 
lymphedema. 
Aim 2: To determine if a statistically significant difference exists in cystic hygroma prevalence 
between those with and without lymphedema. 
Aim 3: To ascertain the prognosis of people with cystic hygromas and lymphedema.  
1.2 BACKGROUND AND SIGNIFICANCE 
1.2.1 Lymphatic System 
The lymphatic system is a network of organs and vessels that serves different functions.  One 
function of this system is the collection of excess interstitial fluid that was not absorbed by the 
surrounding tissues or the vascular network.  Lymph is the fluid that travels through the 
lymphatic system.  Muscle contractions provide the force necessary to move the lymph fluid 
through the lymphatic system to ultimately return this fluid to the circulatory system.  Before this 
can happen though, the lymph must travel through the lymph nodes which filter the lymph for 
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damaged cells, debris, waste, foreign agents, and cancer cells.  These lymph nodes contain 
different white blood cells including lymphocytes for this purpose.  Therefore, the lymphatic 
system is not only involved in transport, it is also involved in aiding the immune system [1, 2].     
1.2.2 Lymphedema  
Lymphedema is the swelling usually in the arm(s) and/or leg(s) from partial malformation, 
removal, blockage, or damage of the lymphatic system [3].  It is estimated that 0.133% - 0.144% 
of the population has lymphedema, but this could be an underestimate due to lack of diagnosis or 
misdiagnosis [4-6].  Complications can occur due to lymphedema such as heaviness or tightness 
feelings in the extremities.  The range of motion can be restricted.  Pain, aching, discomfort, and 
pressure sensations could develop.  A person with lymphedema is at an increased risk of 
infections including bacterial skin infections (cellulitis) and infection of the lymph vessels 
themselves (lymphangitis).  Affected skin can become hardened.  Untreated lymphedema can 
lead to a rare form of cancer called lymphangiosarcoma [3].  Some people with lymphedema can 
also have a negative body image.      
Although there is no cure for lymphedema, different treatments are available.  Light 
exercise can help drain excess lymph.  Wrapping the affected arm or leg can help the lymph flow 
from the limb to the trunk of the body.  Manual lymph drainage is a special type of massage 
performed by a trained expert to help flow the lymph to the trunk of the body.  Not everyone 
with lymphedema should have this done.  Exclusion criteria include: skin infection, cancer, 
congestive heart failure, blood clots, and regions of the body that have received radiation 
therapy.  Compression of the affected arm or leg with a compression garment or with an 
intermittently-inflating sleeve is another treatment option.  Ultimately, the goal is to help move 
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the lymph out of the affected extremities and to the trunk of the body.  Surgery to alleviate the 
swelling is another option; however, surgery can also exacerbate swelling if damage to the 
lymphatic vessels or lymph nodes occurs [3].   
There are two types of lymphedema, primary and secondary.  Primary lymphedema is a 
genetic or inherited condition that causes developmental problems with lymph vessel formation 
or function.  Secondary lymphedema is caused by external factors such as infection, cancer, 
radiation, and surgery.  A classic example of secondary lymphedema is surgical removal or 
injury to lymph nodes and lymphatic vessels to check for the spread of breast cancer.  Radiation 
treatment for cancer can also damage lymphatic vessels leading to lymphedema.  Cancer itself or 
certain infections such as parasites can block lymphatic vessel(s) which then causes swelling.  
Secondary lymphedema caused by infections are more common in tropical areas of the world, 
especially in developing countries [3]. 
 
1.2.3 Genetic Causes of Primary Lymphedema 
The prevalence of primary lymphedema for those younger than 20 years old may be 1.15 out of 
100,000 [4, 7].  Congenital lymphedema is present within the first two years of life.  
Lymphedema praecox typically appears around the age of puberty, but can be present for 
someone in his/her 20s.  Lymphedema tarda usually develops after age 35 [4]. 
 When a hereditary pattern of primary lymphedema is present in a pedigree, it most likely 
follows an autosomal dominant pattern of inheritance; however, autosomal recessive inheritance 
has also been reported [4].  One important example of autosomal dominant primary lymphedema 
is lymphedema-distichiasis (LD) syndrome [4, 8].  This syndrome typically manifests during 
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puberty and involves distichiasis which means that extra eyelashes (sometimes an entire row) 
form posterior to the lid margins.  These eyelashes tend to point downward and can cause severe 
damage to the cornea.  Distichiasis is 94.2% penetrant in most LD families.  Ptosis (31%), 
congenital heart disease (7%), cleft palate (4%), spinal extradural cysts, and early onset varicose 
veins (49%) have also been reported in association with lymphedema-distichiasis syndrome [4, 
8].  The only known genetic causes of LD syndrome are mutations in the FOXC2 gene.  FOXC2 
is a forkhead transcription factor gene [8].   
 Mutations in the FMS-Related Tyrosine Kinase 4 (FLT4) gene (also known as VEGFR3) 
will yield an autosomal dominant congenital primary lymphedema condition called Milroy 
disease [5, 8].  In a study by Brice et al., 90% of those with a mutation in this gene developed 
lower extremity lymphedema.  Swelling was present at birth except for two cases.  Cellulitis 
(20%), large leg veins (23%), upslanting toenails (10%), and development of papillomas (10%) 
are associated with Milroy disease.  For men, hydrocele (37%) was the most prevalent finding 
besides lymphedema [9].   
 Single gene mutations are not the only genetic cause of primary lymphedema, which can 
also occur in individuals with Turner syndrome.  It is estimated that 17% - 30% of those with 
Turner syndrome have lymphedema [10-12].  This is a condition that affects development in 
females and it is estimated that 1/2,500 female births have Turner syndrome, which is even more 
common among miscarriages and stillbirths.  Women with Turner syndrome tend to be of short 
stature and infertile due to lack of ovarian function.  They also exhibit a webbed neck, skeletal 
anomalies, heart problems, and kidney problems. Women with Turner syndrome do not have two 
complete X chromosomes.  Having only one copy of the SHOX gene (located on the X 
chromosome) probably causes the skeletal issues associated with Turner syndrome [13].   
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 Other symptoms of Turner syndrome include frequent middle ear infections and potential 
deafness during childhood.  Some girls may have problems with memory skills, fine motor skills, 
and math.  Females with this condition can have a broad chest with widely-spaced nipples.  Arms 
may turn out slightly from the elbow.  High blood pressure, scoliosis, and minor eye problems 
are also possible.  Hypothyroidism, slight risk of diabetes, and osteoporosis are also concerns 
[13].    
 It has also been shown that Turner syndrome can lead to cystic hygromas [14]. 
 
1.2.4 Cystic Hygromas 
Cystic hygromas are fluid-filled growths that typically occur in the neck or head area due to 
partial malformation of the lymphatic system.  They can be detected via ultrasound during 
pregnancy, at birth, or within the first two years of life [15].  Cystic hygromas in the neck region 
occur in 1/6,000 live births and 1/750 miscarriages [14].  Some cystic hygromas resolve during 
pregnancy; however, 85% of cystic hygromas grow larger than the fetus’s head.  Cystic 
hygromas can cause: extra folds of skin at the neck (webbed neck), some tissue swelling, non-
malignant tumors on the skin known as lymphangiomas, and hydrops where there is too much 
fluid within the baby’s body.  Hydrops is very serious and can lead to miscarriage or death [15]. 
 Treatment options for cystic hygromas include monitoring, surgery, and sclerotherapy.  
Surgical removal of the fluid-filled cysts is one treatment option.  It should be noted that a cystic 
hygroma may come back after surgery in 10% - 15% of cases.  Sclerotherapy is another 
treatment option that does not involve surgery.  Ultrasound is used to guide the needle into the 
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cyst.  Medicine is injected which causes the lymphatic vessels and the cyst itself to decrease in 
size [15]. 
 Cystic hygromas can cause hydrops as well as cosmetic concerns.  It is important to note 
that additional complications, such as infections, can arise.  Sometimes the cystic hygroma will 
form an abscess which needs to be drained.  Antibiotics, antipyretics, and analgesics can be used 
to help treat the infected cystic hygroma.  Cystic hygromas can spontaneously bleed.  The cysts 
can become very hard when this occurs, and surgery may be required in these situations.  
Respiratory difficulties and trouble swallowing can also occur if the cystic hygroma is in the 
neck and/or oral cavity [16].   
 Environmental causes of cystic hygroma include maternal viral infections and fetal 
alcohol syndrome [15].  There are also different genetic causes for cystic hygromas including 
Turner syndrome [14].  However, the cause of cystic hygroma is often unknown.          
 
1.2.5 Genetic Causes of Cystic Hygromas 
Between 50-60% of cystic hygroma cases involve an abnormal karyotype or genetic syndrome 
[14, 15, 17, 18].  Turner syndrome and Trisomy 18 each contributed approximately 15.4% to the 
cause of cystic hygromas according to Tanriverdi et al. [14].  However, Hoswarth et al. showed 
in his study that Turner Syndrome is the most common chromosomal cause of cystic hygromas 
with 33% of pregnancies with cystic hygromas having Turner Syndrome [18].   Other genetic 
conditions associated with cystic hygromas include: trisomy 21 (Down syndrome), trisomy 13, 
Noonan syndrome, and Roberts syndrome [15]. 
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 Trisomy 18 is caused by an extra copy or piece of chromosome 18.  It affects 1/3,000 - 
1/8,000  live births and 1/2,500 pregnancies, but the incidence goes up with maternal age [19, 
20].  Less than 10% of those born with this condition will live to 1 year of age and a majority 
will die in less than a week after birth.  Besides cystic hygromas, trisomy 18 can also include: 
heart defects, kidney problems, gastrointestinal issues, polyhydraminos, low-set malformed ears, 
clenched hands during and after pregnancy, rocker bottom feet or clubfeet, facial characteristics, 
delayed growth, micrognathia, microcephaly, hernias, lung anomalies, diaphragm anomalies, 
abdominal wall anomalies, ureter anomalies, and severe intellectual disability [14, 15, 19, 20].  
 Trisomy 21 (Down syndrome) is caused by an extra copy or piece of chromosome 21.  
Overall, it affects 1/800 live births, but the incidence goes up with maternal age [21].  Besides 
cystic hygromas, trisomy 21 can also affect: the heart, the central nervous system including some 
cognitive impairment and autistic behaviors, the gastrointestinal system, the endocrine system 
(hypothyroidism and diabetes), the ears and eyes, growth, and the musculoskeletal system, as 
well as cause leukemia [15, 21]. 
 Trisomy 13 is caused by an extra copy or piece of chromosome 13.  It affects 1/10,000 
live births, but the incidence goes up with maternal age.  Less than 10% of children born with 
this condition will live to the first year of life and 80% die before 1 month [22].  Besides cystic 
hygromas, trisomy 13 can also affect other systems [15, 22].  Some characteristics of trisomy 13 
include: scalp defects, holoprosencephaly, cleft lip and palate, single palmar crease, polydactyly, 
eye and ear problems, abnormal genitalia, and severe intellectual disability.  About 80% of those 
born with trisomy 13 have cardiovascular issues.  [22]. 
 Ten to fifteen percent of Noonan syndrome is due to an unknown cause, but the rest of 
Noonan syndrome is caused by mutations in one of several genes including: PTPN11, SOS1, 
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RAF1, and KRAS [21, 23].  Noonan syndrome follows an autosomal dominant pattern of 
inheritance, but de novo mutations can occur [21].  Noonan syndrome affects 1/2,500 - 1/1,000 
people and characteristics of this syndrome include cystic hygromas and webbed necks [15, 24, 
25].  This syndrome can also involve: a different facial appearance, congenital heart defect, short 
stature, minor eye problems (for 95% of individuals with this syndrome), bleeding problems, 
undescended testicles for males,  and developmental delay.  The chest shape can be affected 
where the nipples are widely-spaced with pectus carinatum for the upper portion of the chest and 
pectus excavatum for the lower portion of the chest  [24, 25]. 
  Roberts syndrome follows an autosomal recessive pattern of inheritance and is caused by 
mutations in the ESCO2 gene which is located in 8q21.1 [26].  Roberts syndrome can cause 
cystic hygromas and hypomelia which may affect all four limbs.  Hypomelia occurs when the 
hands and/or feet are close to the trunk of the body due to underdeveloped limb formation.  
Growth deficiency beginning in utero also occurs in individuals with Roberts syndrome.  
Craniofacial anomalies can occur including: micrognathia, microcephaly, cleft lip and palate, and 
an opening in the frontal section of the skull.  People affected with this condition may have mild 
or severe intellectual disability [15, 26].   
 The FoxF and FoxC gene families are involved in early embryonic development 
specifically with the mesoderm cells.    FOXF1 and FOXC2 genes are forkhead transcription 
factors in these gene families.  Garabedian et al found that deletion of these two genes within the 
16q24.1 region was associated with cystic hygroma, fetal hydrops, and a single umbilical artery 
on a terminated fetus (22 weeks gestation) via whole genome array comparative genomic 
hybridization (aCGH).  Previous karyotype and FISH for chromosomes 13, 18, 21, X, and Y 
were normal.  FISH confirmed the 16q24.1 deletion (1.1 megabases) [27].  About 50% - 60% of 
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fetuses with cystic hygromas will have a chromosomal condition detected by karyotype [14-17, 
26].  The authors argue that whole genome aCGH will detect an additional 5.2% of chromosomal 
abnormalities (when copy number variants are excluded) that would not be detected by 
karyotype [27, 28]. 
 
1.2.6 Significance 
This study aims to establish if a connection truly exists between primary lymphedema and cystic 
hygromas.  Both primary lymphedema and cystic hygromas are caused by dysregulation of the 
lymphatic system so a connection between them is theoretically possible.  This study will also 
investigate the prognosis of those affected with both lymphedema and cystic hygromas.  
Previous surveys sent out to participants of the Lymphedema Family Study showed 7 individuals 
affected with both primary lymphedema and cystic hygromas in the free response section.  This 
project explicitly asks about cystic hygromas and lymphedema through a questionnaire.   If an 
association exists between primary lymphedema and cystic hygromas, then this knowledge can 
help predict prognosis and provide appropriate care.                    
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2.0  MATERIALS AND METHODS 
2.1 DATA COLLECTION 
2.1.1 Patient Population 
The patient population consisted of male and female participants who have previously given 
consent to the Lymphedema Family Study.  Inclusion criteria include those who have a diagnosis 
of lymphedema who have submitted biological samples in the past, and those who are related to 
someone with a diagnosis of lymphedema and have submitted biological samples in the past.  No 
individual who meets the above criteria was excluded if he/she desired to participate. 
2.1.2 Patient Recruitment 
Only those already recruited in the past for the Lymphedema Family Study and who voluntarily 
submitted biological samples were contacted via mail.  Depending on the responses to the 
questionnaire some participants were contacted with a phone call for follow-up. 
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2.1.3 Informed Consent 
Participants have provided informed consent previously for the Lymphedema Family Study. 
 
2.1.4 Sample 
The total number of eligible participants was 1,628 which were all recruited through the 
Department of Human Genetics at the University of Pittsburgh. 
 
2.1.5 Tools 
An introduction letter (Appendix A) and a cystic hygroma questionnaire (Appendix B) were 
mailed to all of the participants.  This questionnaire inquired about lymphedema status, increased 
nuchal thickness, nuchal edema, cystic hygroma, and septated cystic hygroma.  Prognosis of 
these medical issues was asked in the questionnaire as well as affected family members.  The 
Progeny database and physical records were used as tools for conducting this project, including 
contacting participants. 
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2.1.6 Questionnaire Distribution 
Questionnaire distribution began in January 2015.  Questionnaires were sent to participants by 
mail.  Participants were asked to return the questionnaires within 10 days of receiving the 
materials. 
 
2.1.7 Statistical Analysis 
Descriptive statistics were used.  Confidence intervals and Fisher’s exact test were used.  For the 
free-response sections of the questionnaire, qualitative analysis was used.   
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3.0  RESULTS 
3.1  DESCRIPTIVES 
3.1.1 Entire Sample 
There are 1,628 total individuals from 247 families that make up this entire sample.  These are 
the individuals who voluntarily donated biological samples in the past to the Lymphedema 
Family Study.  There are 605 individuals from this sample who are affected by lymphedema 
(37.2%), 834 individuals without lymphedema (51.2%), and 189 individuals whose lymphedema 
status has not been determined (11.6%).  
 Out of 1,628 individuals who were mailed questionnaires, 333 were returned due to an 
invalid current mailing address (20.5%).  Of these 333 mailings that were returned as 
undeliverable, 88 had email addresses listed in Progeny, and were therefore contacted via email.  
There were an additional 182 individuals out of the original 1,628 who did not have a complete 
address on file (11.2%), 60 of whom were also alternatively contacted via email. 
 Out of the 1,628 individuals who were mailed a questionnaire, 316 responded (19.4%) 
with only one who reported an increased nuchal thickness (0.3%).  No respondent reported 
nuchal edema or a septated cystic hygroma.     
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3.1.2 Response Sample 
There were 316 individuals out of 1,628 respondents to the questionnaire (19.4%).  Out of the 
316 individuals who responded: 123 replied that they have or had lymphedema (38.9%), 17 
replied that they do not know if they have lymphedema (5.4%), and 176 replied that they do not 
have lymphedema (55.7%).  Table 1 compares the data from the questionnaire respondents to the 
entire original sample.  Data from the questionnaires of the response sample was compared to 
data in Progeny for the entire original sample and updates were made in Progeny for the entire 
original sample.    
 
Table 1: Comparison of Lymphedema Status Between Those That Responded to the Entire Sample 
 
 Response Sample Entire Sample 
Lymphedema 123/316 (38.9%) 605/1,628 (37.2%) 
No Lymphedema 176/316 (55.7%) 834/1,628 (51.2%) 
Lymphedema Status 
Unknown 
17/316 (5.4%) 189/1,628 (11.6%) 
 
 
• 95% Confidence Interval for Lymphedema is (0.335, 0.443) which includes the known 
entire sample proportion (pi) of 0.372 so there is no statistically significant difference 
between the response sample and the entire sample.  This result is desired.   
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• 95% Confidence Interval for No Lymphedema is (0.502, 0.612) which includes the 
known entire sample proportion (pi) of 0.512 so again there is no statistically significant 
difference between the response sample and the entire sample.  This result is desired. 
• 95% Confidence Interval for Unknown Lymphedema Status is (0.029, 0.079) which does 
not include the known entire sample proportion (pi) of 0.116 so there is a statistically 
significant difference between the response sample and the entire sample.  This result is 
not desired.   
 Overall, the response sample is representative of the entire sample with the exception of 
the Unknown Lymphedema Status proportions.  These confidence intervals were used to check 
for potential bias of those who responded.     
3.2 QUALITATIVE 
3.2.1 Cystic Hygroma and Nuchal Thickness 
As stated in the Introduction, there were 7 individuals mentioned in the free response section of 
the original Lymphedema Family Study survey who had lymphedema and cystic hygromas plus 
another individual with lymphedema that may have had a cystic hygroma.  This was the 
inspiration for this project.  Table 2 shows this data as well as increased nuchal thickness (NT), 
nuchal edema (NE), and nuchal fold (NF) for fifteen individuals. 
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Table 2: Original Lymphedema, Cystic Hygroma, and Nuchal Data 
Individual Phenotype Lymphedema Affection Status 
1 CH and Fetal Hydrops: Not Turner 
Syndrome* 
Affected 
2 Subdural Hygroma (not CH) Affected 
3 CH and NT Affected 
4 NT Affected 
5 NF Unaffected (current age 19) 
Average age of onset for family (7.9) 
6 CH Affected 
7 CH? Noonan’s? Indeterminate  
(age at original survey - 6) 
Average age of onset for family (16.7) 
8 Distichiasis and NF Affected 
9 CH Affected 
10 CH Affected 
11 NT/CH Affected 
12 CH/hydrops* Affected 
13 (sibling to # 14) NT Indeterminate (miscarriage) 
Average age of onset for family (13.2) 
14 (sibling to # 13) NT Indeterminate (current age 2) 
Average age of onset for family (13.2) 
15 NT to CH to hydrops* Affected 
*Individuals captured on original survey and cystic hygroma questionnaire 
Following are the replies to the cystic hygroma questionnaire. 
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Family A replied back “Child Female Did Not Survive Birth With Turner’s Syndrome”.  This 
family was not able to be contacted to verify lymphedema or cystic hygroma.  She was 
diagnosed at 19 weeks of gestation and was stillborn.  Her brother has lymphedema since birth.  
No other family members have lymphedema.  The pedigree for this family is in Appendix C.   
 An individual from Family R states, “My brother,…, had a child with a thick neck 
detected in utero.  At birth it was resolved.” Lymphedema or cystic hygroma status was 
unknown due to failure to contact family.  The individual that had a “thick neck” is now 12-14 
years old with no lymphedema.  There is a hereditary pattern of lymphedema with three 
generations affected including the father of the child with a “thick neck”.  The average age of 
onset of lymphedema for this family is 22.4 years.  The pedigree for this family is in Appendix 
D. 
 Family G stated “Nuchal thickness in utero one baby that did not survive birth 
(miscarriage at 17-18 weeks).  In utero, my daughter (current age 10) had increased nuchal 
thickness noted as part of the Down Syndrome test but has never been tested or noted as a 
problem since.  She is ‘very normal’ ”.  No genetic testing was done for these children and 
neither one has been diagnosed with lymphedema.  Four generations affected with lymphedema, 
but not the mother (age 50) of these two children.   The average age of onset of lymphedema for 
this family is 28 years.  The pedigree for this family is in Appendix E.   
   One 45 year old man from Family P commented on his own lymphedema (which did not 
increase or decrease over time), genetic test results in the family, and cystic hygroma in the 
family. This is what he wrote with respect to himself. “Lymphedema onset at puberty, 
approximately age 15. (Distichiasis present since childhood)…Lymphedema-distichiasis 
syndrome has not severely impacted my quality of life, but it has frequently been cause for 
 18 
discomfort or for worry over peer acceptance, health, and safety.  It regularly affects my choice 
of clothing.  It has twice caused great illness when infections entered my body through my feet.”  
This is what he wrote down for his family.  “My maternal grandmother…, mother…, and 
sister… have lymphedema-distichiasis syndrome, and have had the FOXC2 gene mutation 
identified through this U of Pittsburgh lymphedema family study.  Most importantly, my 3-year-
old son, [R for confidentiality], displayed cystic hygroma in utero.  My wife’s…OB/GYN office 
discovered it on the back of [R’s] neck during a routine ultrasound when she was pregnant, 
prompting them to refer our case to a high-risk perinatal office … and starting what were some 
very scary months for us in late 2010 and early 2011.  Three months after it was discovered on 
[R’s] neck, the cystic hygroma was discovered to be receding.  When [R] was born on June 29, 
2011, no remnant of the cystic hygroma was visible, though there was a little bit of excess skin 
on the back of his neck.  That excess skin disappeared as [R] grew.”  A sister of the man who 
wrote this also replied back to the questionnaire.  She describes her own lymphedema which has 
not increased or decreased over time.  “Age 30, not related to pregnancy, Location: calves, 
ankles and feet.  I believe it was triggered by a very long airplane flight.” And she wrote about 
her daughter.  “My daughter (15) has not been officially diagnosed, nor does she presently show 
swelling, but she has the trademark family ingrown eyelashes.  When she was born she had extra 
skin at the back of her neck, but there was no cause for concern and it went away as an infant.”  
There is a FOXC2 mutation in this family and it is an insertion of cytosine at base-pair position 
609 (c.609insC) which yields a protein with a termination at amino acid position 463 (p.463X).  
Individuals in this family with this mutation are the 45 year old man, his mother, and his 
maternal grandmother.  This exact mutation in this family was found by Finegold and Ferrell et 
al. in 2001 under “Family F” in the journal article.  “Family F” in this journal article is “Family 
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P” for this questionnaire study [29].  It is important to note that four generations of this family 
are affected by lymphedema-distichiasis.  The average age of onset of lymphedema for this 
family is 17.6 years.  The pedigree for this family is in Appendix F.   
 The mother in Family C noted that one of her sons (C) has Milroy’s disease (primary 
lymphedema) since birth and that her other son (P) had non immune hydrops and cystic 
hygroma.  C also has an 8p11.23 deletion.  P was stillborn at 27 weeks after an intrauterine fetal 
demise.  He was also diagnosed with lymphedema, but had a normal karyotype and microarray.  
No other family members have lymphedema.  This individual was already captured on the older 
survey and is individual 12 in Table 2.  The pedigree for this family is in Appendix G.   
 Family J exhibits five generations affected with lymphedema.  One individual mentioned 
her own lymphedema (did not increase or decrease with time) diagnosis as well as other family 
members.  “Primary lymphedema dx approx. 1998 at age 27.  Both lower limbs with some 
abdominal involvement.  Also I have distichiasis as do my 2 daughters.  I started showing 
symptoms at age 14 and they increased after my first pregnancy (the stillborn with cystic 
hygroma).  It worsened until my diagnosis and treatment at 27.  It has affected my quality of life 
by reducing the activity level I’m able to enjoy with my family.  Also, it is somewhat 
emotionally draining and taxing on a person’s self-esteem.  I had a stillborn baby girl in 1992 at 
28 weeks gestation.  She was diagnosed with cystic hygroma with fetal hydrops as the cause of 
death.”  The girl who was stillborn also had a diagnosis of lymphedema.  An amniocentesis was 
done during pregnancy and she did not have 45,X (Turner syndrome).  This individual was 
already captured on the previous survey.  She is Individual 1 in Table 2.  The mother did have 
genetic testing for herself and she has a FOXC2 mutation (c.377T>C, p.L126P).  Although both 
of her daughters have distichiasis, only the elder (age 21) has developed lymphedema by the time 
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of this survey.  The younger daughter is 17 years old.  The average age of onset of lymphedema 
for this family is 17.1 years.  The pedigree for this family is in Appendix H.         
 The mother in Family K wrote that “My daughter ([L] - enrolled) was diagnosed with 
increased NT at 13 weeks that quickly progressed to a cystic hygroma and fetal hydrops.  She 
lived till 23 weeks” of gestation. L was also noted to have pleural effusion, ascites, 
lymphangiectasia, and hydronephrosis.  She was conceived through her parents’ gametes via in-
vitro fertilization.  L, her father, her paternal uncle, and her paternal grandfather were all 
diagnosed with lymphedema with a FOXC2 mutation present in both L and her father 
(c.223insT; p.Tyr75Leu fs*388).  L has been captured on the previous survey.  She is individual 
15 in Table 2.  The average age of onset of lymphedema for this family is 14.4 years.  The 
pedigree for this family is in Appendix I. 
3.3 TESTING FOR SIGNIFICANCE 
3.3.1 Testing for Significant Difference of Cystic Hygroma Prevalence Between Those 
With and Without Lymphedema (Aims 1 and 2) 
There are three people with cystic hygromas out of 123 with lymphedema (2.44%).  There is also 
one person with cystic hygromas out of 176 without lymphedema (0.57%).  Fisher’s exact test 
was used to examine if there was a statistically significant difference of cystic hygroma 
prevalence between those with and without lymphedema.  This test yielded a p-value of 0.3094.  
Since the alpha level is set at 0.05, this means that the difference seen was not statistically 
significant.   
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4.0  DISCUSSION 
4.1 AIM 1: ASCERTAINING THE PROPORTION OF PEOPLE WITH CYSTIC 
HYGROMAS OF THOSE WITH AND WITHOUT LYMPHEDEMA 
This Aim was achieved with data from the cystic hygroma questionnaire.  Of the 123 surveys 
sent back from individuals with lymphedema, 3 also had a history of cystic hygromas (2.44%).  
Of the 176 surveys returned from individuals without lymphedema, 1 also had a previous cystic 
hygroma (0.57%).  If one was to include increased nuchal thickness due to the one case that had 
an increased nuchal thickness develop into a cystic hygroma (Family K), then there were 4 cases 
of cystic hygroma/increased nuchal thickness (1 cystic hygroma + 3 increased nuchal thickness) 
out of 176 people without lymphedema (2.27%). “Thick neck” or thickened skin at the back of 
the neck were not included because these descriptions are not diagnostic, but can be suggestive 
of past cystic hygroma. 
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4.2 AIM 2: TO DETERMINE IF A STATISTICAL SIGNIFICANT DIFFERENCE 
EXISTS IN CYSTIC HYGROMA PREVALENCE BETWEEN THOSE WITH AND 
WITHOUT LYMPHEDEMA 
The Fisher’s exact test was performed to achieve Aim 2.  Based on a p-value of 0.3094 which is 
greater than the alpha level of 0.05, it is determined that the difference in cystic hygroma 
prevalence between those with (2.44%) and without lymphedema (0.57%) is not statistically 
significant.  With only three confirmed cases of cystic hygroma with lymphedema and one 
confirmed case of cystic hygroma without lymphedema, this result is not unexpected due to the 
low numbers of individuals affected with cystic hygroma.  In addition, it was not useful to 
include increased nuchal thickness cases, since these were only reported among the individuals 
without lymphedema (2.27%) which only serves to weaken the significance of this result.   In 
this situation, Fisher’s exact test would yield a p-value of 1.0 meaning that there was absolutely 
no statistical significant difference in cystic hygroma/increased nuchal thickness prevalence 
between those with and without lymphedema.   
 It should be noted that the Fisher exact test used may be flawed in this situation.  The one 
individual who was diagnosed in utero with cystic hygroma, but was not diagnosed with 
lymphedema may develop lymphedema in the future because he is only three years old and the 
average age of onset for lymphedema in this family (Family P) is 17.6 years.  He has a 50% 
chance of inheriting the FOXC2 mutation from his father and may develop lymphedema in the 
future.   
 The three individuals who have been diagnosed with both lymphedema and cystic 
hygromas (all died before birth) make up 2.44% of those respondents with lymphedema, but the 
general population prevalence of cystic hygromas for miscarriages is 1/750 or 0.1333% (18.3-
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fold difference) [14].  This greatly strengthens the argument that there should be a higher 
prevalence of cystic hygromas for those with lymphedema compared to those without 
lymphedema since 18.3-fold difference is a big difference.         
4.3 AIM 3: TO ASCERTAIN THE PROGNOSIS OF PEOPLE WITH CYSTIC 
HYGROMAS AND LYMPHEDEMA 
The only individuals from the cystic hygromas questionnaire with both cystic hygromas and 
lymphedema were the three babies that died in utero.  One of the three cases that had both cystic 
hygroma and lymphedema in utero had increased nuchal thickness at 13 weeks which developed 
into a cystic hygroma and fetal hydrops (Family K).  She and her father both harbored a FOXC2 
mutation. The average age of onset of lymphedema for family K is 14.4 years.    One of the other 
lymphedema/cystic hygroma cases has a mother with a missense FOXC2 mutation (Family J).  
The average age of onset of lymphedema for this family is 17.1 years.    In family C, the son who 
died in utero (had both cystic hygroma and lymphedema) has a brother who is currently 4 years 
old who has Milroy’s disease since birth.  No other family members in family C have 
lymphedema.   All three cases that had both cystic hygromas and lymphedema were previously 
captured on the earlier survey in the free response section that was the inspiration for this project.   
 There was one case of cystic hygroma that did not develop lymphedema in utero, but he 
is currently 3 years old and is from a family with significant primary lymphedema and a known 
truncating FOXC2 mutation (Family P).  It is possible that he did not inherit the FOXC2 
mutation (no genetic testing was performed on him), but the possibility of developing 
lymphedema (specifically lymphedema-distichiasis) in the future cannot be ruled out.  His cystic 
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hygroma disappeared as well as the thick skin at the back of his neck.  His cousin was born with 
extra skin at the back of her neck and has distichiasis, but does not have lymphedema currently.  
She is now 15 years old.  The average age of onset of lymphedema for this family is 17.6 years.  
Lymphedema-distichiasis typically has onset during puberty (not congenital) [4, 8].         
 Family G did have one child who died in utero after being diagnosed with an increased 
nuchal thickness, but the mother also has a daughter who is currently 10 years old who had an 
increased nuchal thickness in utero.  The average age of onset of lymphedema for this family is 
28 years so the daughter who is currently 10 years old may develop lymphedema in the future.       
 For people with lymphedema, the common responses to the questionnaire were pain, 
swelling, difficulty finding the right clothes, and difficulty with mobility.  Some have reported 
being embarrassed or having their own self-esteem or self-body image harmed.  There were 
some who reported not being affected that much by the lymphedema. 
4.4 IMPLICATIONS AND PUBLIC HEALTH SIGNIFICANCE 
Lymphedema is an incredibly complex disease that can have significant burdens both physically 
and psychologically.  Cystic hygromas can cause significant cosmetic and medical complications 
including miscarriages and stillbirths.  Approximately 50-60% of individuals with cystic 
hygromas have a chromosomal or genetic syndrome that also makes medical management and 
treatment more complex [14, 15, 17, 18].  Both lymphedema and cystic hygromas are medical 
issues involving the lymphatic system.  The main objective of this project was to determine if an 
association exists between cystic hygromas and lymphedema, the presence of which may help 
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predict prognosis and provide appropriate care.  There is some evidence that this association 
exists, but it is not statistically significant. 
4.5 LIMITATIONS 
One limitation of this project was the low response rate to the cystic hygroma questionnaire 
(19.4%).  Participating in this questionnaire was voluntary.  A strength of this project; however, 
was that those who did respond were representative of the lymphedema affection status of the 
original sample.  
 Another limitation of this project was the lack of access to medical records, both paper 
and electronic, except for what has been previously provided to us by the participants 
themselves.  One difficulty of a retrospective study is that participants may not have access to 
previous medical records or may not recall certain medical information.  Medical records may 
contain information that participants and their family members do not know or remember.  
Participants of the Lymphedema Family Study come from all over the United States and all over 
the world.  The United States is moving toward an all-electronic medical record system which 
may not be accessible through Progeny in the future due to privacy concerns including 
H.I.P.A.A.  Many paper medical records may not exist anymore due to destruction. 
 Since the Lymphedema Family Study is 20 years old, there is a high probability that 
many participants have moved, resulting in invalid contact information stored in Progeny.  In 
fact, 20.5% of cystic hygroma questionnaires were returned as undeliverable.  Although attempts 
were made to contact these individuals via email, as well as those whose addresses were not 
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listed in Progeny (11.2%) - only 28.7% of these individuals had an email address listed in 
Progeny.   
 Another limitation of this project was that the only cases that had both cystic hygromas 
and lymphedema were cases that were already captured in the original survey for the 
Lymphedema Family Study, yet only three of these were reacquired for this project.  The low 
numbers of increased nuchal thickness and cystic hygromas for both those with and without 
lymphedema resulted in data not reaching statistical significance.   
 One reason for the low numbers of cystic hygroma cases could be due to underreporting.  
Perhaps more individuals had a cystic hygroma in utero, but were not diagnosed because the 
screening technology was not readily available at the time.  Prenatal ultrasounds may not have 
existed for many of the participants or they may not have been performed for most individuals 
included in the original study.  Offering prenatal ultrasounds as standard-of-care, particularly 
first trimester screening is a relatively recent phenomenon, but one that will likely continue to 
grow with time. 
4.6 FUTURE RESEARCH 
The best way to truly determine if an association exists between primary lymphedema and cystic 
hygromas is to have a multi-year, multi-site prospective study.  If cost is a major concern, then 
this study can be done on families with lymphedema only.  This study would be performed at 
medical institutions that offer prenatal ultrasounds as standard-of-care.  Those that have been 
diagnosed with having a cystic hygroma in utero would be followed regardless of pregnancy 
outcome (miscarriage, stillbirth, or live birth).  For those that are live birth, they would be 
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followed for many years in order to maximize the chance that lymphedema diagnoses would be 
recorded.  This would be an ambitious project, but could potentially aid future individuals with 
cystic hygromas due to any cause, including hereditary lymphedema.   
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APPENDIX A: INTRODUCTION LETTER 
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APPENDIX B: CYSTIC HYGROMA QUESTIONNAIRE 
30 
APPENDIX C: FAMILY A PEDIGREE 
0
"... fine motor skills are affected
by his hand and arm swelling... balance is also  
affected by his lack of mobility in his  
arms.  When bandaged he is slow to use his hands."
Stillborn child was diagnosed with Turner syndrome (gestational age 19 weeks).
LE Affection Status = Affected
I-Yellow Nails? = Don't Know
 
 
Subtext Legend: 
Age at onset (if applicable) 
Phenotype details 
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APPENDIX D: FAMILY R PEDIGREE 
 
25
LE onset @ 25
w/ 2nd preg
18 22 27
"Lymph" CA
12 15
sores on hands/fingers
are slow to heal
25 35
LE left calf/ankle/foot
since C/S w/ 3rd child
leg ulcers/swell  
since HS/early 20s
ptosis in 1 eye when tired
thick neck
in utero
resolved at 
birth
3 3 3 2
spontaneous
chylothorax @ 
9 days (resolved)
LE Affection Status = Affected
I-Distichiasis? = Don't Know
I-Ptosis? = Yes
I-Yellow Nails? = Don't Know
I-Kidney Problems? = Yes
 
Subtext Legend: 
Age at onset (if applicable) 
Phenotype details 
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APPENDIX E: FAMILY G PEDIGREE 
Subtext Legend:
Age at onset (if applicable)
Phenotype details
20
onset @ 62
dx @ 72
ptosis
degen osteo-
arthritis @ 35
Thal Minor
cong cataracts
GERD
d. SCD (MI?)
atrial dilation
NIDDM
3
onset @ 3
dx @ 21
severe LE
cellulitis X 5
BCC @ 60s X 6
Lupus of skin @ 76
onset @ 25
with preg
severe swell
not dx
d. brain CA
severe jaundice
@ 10 and 20
MI @ 69
18
onset @ 18
severe/dx @ 41
varicose veins @ teens
Dr. says not LE
legs swell when
off diuretic
58
lymphoma @ 29
osteoarthritis
DVT L leg @ 58
from long car ride
leg still swells
w/o stockings
obese CHF
obese
SB (in Taiwan) fibromyalgia
lupus/Raynaud's
RA/PA @ 35
ankles swell
(from arthritis?)
16
onset @ 16
dx @ 17
ankles swell
only occ. now
swell w/ all
pregs, heat, 
and standing
varicose veins @ 20
"arthritis
in legs"
ankle pain
Increased NT
16
onset @ 16
dx @ 19
thal minor
65
d. MI
LE onset @ 60s?
dx @ 75
pleural effusions @ 34-60
NIDDM @ 50s
abusive (ETOH)
mild ptosisd. MI
3
d. atrial
dilation
d. 6 strokes 
(1st @ 71)
d. atrial 
dilation
d. MI
NIDDM
ETOH
d. SCD
senility
severe LE
d. aplastic
anemia
8 3 3 3
d. SCD
no 
swell
3
no
swell
3
Increased NT
2
LE Affection Status = Affected
LE Affection Status = Indeterminate
I-Ptosis? = Yes
I-Ptosis? = Don't Know
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APPENDIX F: FAMILY P PEDIGREE 
 
FoxC2 Nonsense Mutation:
c.609insC
p.463X
16
FOXC2 Mutation
14
s/p cleft palate
FOXC2 Mutation
19
23
COPD
Left total knee prosthesis
Multinodular goiter
Varicose veins
FOXC2 mutation
16
"Tremors and dry eyes"
onset @ ?
Pain in groin
Extra skin at 
back of neck (at birth)
Disappeared
Has Distichiasis
Cystic Hygroma 
in utero
disappeared
Extra skin at back
of neck disappeared
LE Affection Status = Affected
LE Affection Status = Indeterminate
I-Distichiasis? = Yes
I-Cleft Palate? = Yes
 
Subtext Legend: 
Age at onset (if applicable) 
Phenotype details 
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APPENDIX G: FAMILY C PEDIGREE 
 
0
onset @ 0
both feet/toes
8p11.23 del
Flt4 negative
big toenails removed @ 2
0
onset @ prenatal
27 wk IUFD
hydrops/cystic hygroma
cardiac defects
nl chroms/microarray
(no 8p del)
8p11.23 del
LE Affection Status = Affected
 
 
Subtext Legend: 
Age at onset (if applicable) 
Phenotype details 
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APPENDIX H: FAMILY J PEDIGREE 
FoxC2 Missense Mutation:
c.377T>C
p.L126P
Subtext Legend:
Age at onset (if applicable)
Phenotype details
d. CHF
swollen legs
32
Swell after accident 
@ early 30s
d. Lung CA (smoker)
Multiple Birth Defects
"possible webbed neck"
"kidney proiblems"
"prune belly"
28
LE both legs - onset 
@ 28 w/ pregnancy
22
LE onset @ 22
working retail (L ankle) and 
flight attendant (R leg)
10
swollen all over @ 10
elephantiasis attributed to 
mosquito bite in India
bilateral ptosis
Parkinson's
no swell
NIDDM/htn
14
R onset @ 14 (ankle sprained)
L onset @ 19 (w/ preg)
Mild dist/ptosis (R eye)
eyelid swell @ 40
nails ridged + curl up
Hypothyroid/Hearing loss @ 8
Varicose Veins @ <10
FOXC2 mutation
obese
0
S B @ 28 wks - cystic 
hygroma + fetal hydrops
amnio done: NOT 45,X
14
onset @ 14 (achy legs)
pneumothorax @ birth
s/p ptosis right eye @ 4
s/p distichiasis
"wide neck"
s/p distichiasis @ 6
no swell yet...
thick legs
knee injury swells
LE Affection Status = Affected
LE Affection Status = Indeterminate
I-Distichiasis? = Yes
I-Ptosis? = Yes
I-Yellow Nails? = Don't Know
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APPENDIX I: FAMILY K PEDIGREE 
 
 
11
onset @ 11
stepped on nail
R leg 2 in > L
heart murmur resolved
FOXC2 mutation
31
Severe Leg Swell 
w/ CH fetus pregnancy
resolved after stillbirth
0
onset @ prenatal
Increased NT at 13 weeks
cystic hygroma -> hydrops
pleural effusions/ascites
lymphangiectasia/hydronephrosis
SB @ 23 wks
IVF w/ ICSI
FOXC2 mutation
no swell
14
onset @ teens
both legs to knee
scoliosis
ovarian cysts
no swell
heart murmur resolved
A&W
16
onset @ teens w/
field hockey accident
bilat (1 leg to hip)
d. brain
aneurysm
no swell no swell
LE Affection Status = Affected
I-Distichiasis? = Yes
I-Heart Defect? = Yes
 FoxC2 Frameshift Mutation c.223insT 
p.Tyr75Leu fs*388 
Subtext Legend: 
Age at onset (if applicable) 
Phenotype details 
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APPENDIX J: IRB APPROVAL LETTER 
 
 
 38 
BIBLIOGRAPHY 
1. Douketis MD, James D. (2013). Overview of the Lymphatic System. The Merck Manual 
 Professional Edition. Merck Sharp & Dohme Corporation, a subsidiary of Merck 
 & Company, Incorporated., Whitehouse Station, N.J., U.S.A. Retrieved from 
 http://www.merckmanuals.com.   
2. Lymphedema Education and Action Network (LE&RN). (2013). FAQs About The 
 Lymphatic System. 261 Madison Avenue, New York, NY 10016. 
 http://lymphaticnetwork.org/living-with-lymphedema/lymphatic-disease/. 
3.  Mayo Clinic. (2014). Diseases and Conditions Lymphedema. 
 http://www.mayoclinic.org/diseases-
 conditions/lymphedema/basics/definition/con-20025603. 
4. Rockson, Stanley G. and Kahealani K. Rivera. (2008). Estimating the Population Burden 
 of Lymphedema.  Ann. N.Y. Acad. Sci. 1131: 147-154. 
 doi:10.1196/annals.1413.014. 
5.  Moffat, C.J. et al. (2003). Lymphoedema: An Underestimated Health Problem. Q. J. 
 Med.  96: 731-738. 
6. Petlund, C. (1990). Prevalence and Incidence of Chronic Lymphoedema in a Western 
 European Country. In Progress in Lymphology, Vol. XII. M. Nishi, S. Uchina & 
 S. Yabuki, Eds: 391-394. Elsevier Science Publishers B.V. Amsterdam, the 
 Netherlands 
7. Smeltzer, D.M., G.B. Stickler & A. Schirger. (1985). Primary Lymphedema in Children 
 and Adolescents: A Follow-Up Study and Review. Pediatrics. 76: 206-218. 
8. Brice, G. et al. (2002). Analysis of the Phenotypic Abnormalities in Lymphoedema-
 Distichiasis Syndrome in 74 Patients with FOXC2 Mutations or Linkage to 
 16q24. J. Med. Genet. 39: 478-483. 
9. Brice, G. et al. (2005). Milroy Disease and the VEGFR-3 Mutation Phenotype. J. Med. 
 Genet. 42: 98-102. doi: 10.1136/jmg.2004.024802. 
10. Findlay, C.A., M.D. Donaldson & G. Watt. (2001). Foot Problems in Turner’s Syndrome. 
 J. Pediatr. 138: 775-777. 
 39 
11. Ruibal Francisco, J.L. et al. 1997. Turner’s Syndrome: Relationship Between the 
 Karyotypes and Malformations and Associated Diseases in 23 Patients. An. Esp. 
 Pediatr. 47: 167-171. 
12. Loscalzo, M.L. et al. (2005). Association Between Fetal Lymphedema and Congenital 
 Cardiovascular Defects in Turner Syndrome. Pediatrics. 115: 732-735. 
13. National Human Genome Research Institute (NHGRI). (2013). Learning About Turner 
 Syndrome. National Institutes of Health (NIH). 
 https://www.genome.gov/19519119. 
14. Tanriverdi, H.A. et al. (2005). Outcome of Cystic Hygroma in Fetuses with Normal 
 Karyotypes Depends on Associated Findings. Eur. J. Obstet. Gynecol. Reprod. 
 Biol. 118: 40-46. 
15. Monroe Carell Jr. Children’s Hospital at Vanderbilt. (2014). Cystic Hygroma. Vanderbilt 
 University Medical Center Retrieved From 
 https://www.childrenshospital.vanderbilt.org/services.php?mid=8705. 
16. Mirza, Bilal et al. (2010). Cystic Hygroma: An Overview. Journal of Cutaneous and 
 Aesthetic  Surgery. 3(3): 139–144. doi: 10.4103/0974-2077.74488.  
17. Tanriverdi, H.A. et al. (2001). Hygroma Colli Cysticum: Prenatal Diagnosis and 
 Prognosis. American Journal of Perinatology. 18(8). 415-420. 
18. Howarth, E.S. et al. (2005). Population-Based Study of the Outcome Following the 
 Prenatal Diagnosis of Cystic Hygroma. Prenatal Diagnosis. 25(4). 286-291.  
19.  Goc, Barbara et al. (2006). Trisomy 18 In Neonates: Prenatal Diagnosis, Clinical 
 Features,  Therapeutic Dilemmas and Outcome. J Appl Genet 47(2). 165-
 170. 
20. Powell-Hamilton MD, Nina N. (2013). Trisomy 18. The Merck Manual  Professional 
 Edition. Merck Sharp & Dohme Corporation, a subsidiary of Merck  & 
 Company, Incorporated., Whitehouse Station, N.J., U.S.A. Retrieved from 
 http://www.merckmanuals.com. 
21. Powell-Hamilton MD, Nina N. (2013). Down Syndrome. The Merck Manual 
 Professional Edition. Merck Sharp & Dohme Corporation, a subsidiary of Merck 
 & Company, Incorporated., Whitehouse Station, N.J., U.S.A. Retrieved from 
 http://www.merckmanuals.com. 
22. Powell-Hamilton MD, Nina N. (2013). Trisomy 13. The Merck Manual  Professional 
 Edition. Merck Sharp & Dohme Corporation, a subsidiary of Merck  & 
 Company, Incorporated., Whitehouse Station, N.J., U.S.A. Retrieved from 
 http://www.merckmanuals.com. 
 40 
23. GeneDx. Noonan Syndrome. https://www.genedx.com/test-catalog/disorders/noonan-
 syndrome/32403/. 
24. National Human Genome Research Institute (NHGRI). (2013). Learning About Noonan 
 Syndrome. National Institutes of Health (NIH). 
 https://www.genome.gov/25521674.  
25. Allanson, Judith E. (1987). Noonan Syndrome. Journal of Medical Genetics. 24. 9-13. 
26. Schule, Birgitt et al. (2005). Inactivating Mutations in ESCO2 Cause SC Phocomelia and 
 Roberts Syndrome: No Phenotype-Genotype Correlation. American Journal of 
 Human Genetics. 77(6). 1117-1128. doi:10.1086/498695. 
27. Garabedian, Matthew J. et al. (2012). Prenatal Diagnosis of Cystic Hygroma Related to a 
 Deletion of 16q24.1 with Haploinsufficiency of FOXF1 and FOXC2 Genes. Case 
 Reports in Genetics. 2012: Article ID: 490408. 1-4. doi:10.1155/2012/490408. 
28. Hillman, S.C. et al. (2011). Additional Information From Array Comparative Genomic 
 Hybridization Technology Over Conventional Karyotyping In Prenatal 
 Diagnostis: A Systematic Review and Meta-Analysis. Ultrasound in Obstetrics and 
 Gynecology. 37(1). 6-14. 
29. Finegold, David N. et al. (2001). Truncating Mutations in FOXC2 Cause Multiple 
 Lymphedema Syndromes. Human Molecular Genetics. 10(11). 1185-1189.        
 doi: 10.1093/hmg/10.11.1185. 
 
 
 41 
